| Course | HCR 555 Pharmaceutical Safety and Risk Management |
|---|---|
| Module | Module 3 |
| Paper type | Regulatory report |
| Length | About 933 words, 6 pages |
| Format | APA 7 student paper |
| School | Arizona State University |
| Program | MS in Regulatory Science |
| Updated | October 2026 |
Free sample paper for HCR 555 Module 3
Watching After Approval: Safety Signals, FDA's Reporting Rules and the Withdrawal of Lorcaserin
Student Name
MS in Regulatory Science, Arizona State University
HCR 555: Pharmaceutical Safety and Risk Management
Instructor Name
Month Day, Year
Watching After Approval: Safety Signals, FDA's Reporting Rules and the Withdrawal of Lorcaserin
Introduction
A drug's safety profile is never complete at approval. Trials enroll thousands of patients at most, for months or a few years, while an approved drug may reach millions for decades. Safety monitoring is the system that fills the gap. This report describes the requirements that govern it, how signals are found and judged and what regulators can do about them, and then examines a drug that left the U.S. market because of a signal from a large trial.
Monitoring and Reporting Requirements
During development, the IND rules oblige sponsors to send the FDA and every investigator reports of serious, unexpected suspected reactions, while large trials add an independent committee that looks at unblinded results as they accumulate. After approval, the manufacturer must review every adverse experience it learns of, from any source, and report serious and unexpected ones to the FDA within 15 calendar days, with periodic reports summarizing the rest (21 C.F.R. § 314.80). Health professionals and patients can report voluntarily through MedWatch. The reports feed the FDA Adverse Event Reporting System, a database the agency mines for unusual patterns. The Food and Drug Administration Amendments Act of 2007 added two tools: authority to require postmarketing studies and safety labeling changes, and the Sentinel system, which queries the electronic health data of large insurers and health systems to study suspected problems in real populations.
Safety Signals and Evaluating Safety Data
A safety signal is information suggesting a new possible risk, or a new aspect of a known one, that warrants further study. Signals come from clusters of spontaneous reports, from disproportionality statistics that show a drug and an event reported together more often than expected, from published case series and, increasingly, from large trials and observational studies. Evaluating a signal means asking whether the association is real and causal: how strong it is, whether it follows a plausible mechanism, whether it depends on dose or duration, whether it appears in other data and whether confounding, such as the condition the drug treats, could explain it. Spontaneous reports cannot give a true rate, because no one knows how many patients took the drug or how many events went unreported, so randomized data, when available, carry the most weight.
Warnings and Recalls
Recalls are usually voluntary actions by the firm, monitored by the FDA, and are classified by hazard. Class I covers products with a reasonable probability of serious harm or death, Class II covers products that may cause temporary or reversible harm or where serious harm is remote and Class III covers products unlikely to cause harm (21 C.F.R. § 7.3). Most drug recalls address manufacturing problems in particular lots. When the problem is the drug itself, the response is a label change or, at the extreme, withdrawal.
| Tool | What it does |
|---|---|
| Labeling change | Adds or strengthens warnings, precautions or contraindications |
| Boxed warning | Places the most serious risks in a box at the top of the label |
| Dear Health Care Provider letter | Tells clinicians directly about a new risk or change |
| Drug Safety Communication | Public FDA notice explaining a risk and advice for patients and clinicians |
| Risk Evaluation and Mitigation Strategy | Requires measures such as medication guides or restricted distribution |
| Recall | Removes specific products from the market, usually lots with a defect |
| Withdrawal | Ends marketing of the drug altogether when risks outweigh benefits |
Example: Lorcaserin
Lorcaserin, sold as Belviq, was approved in 2012 for chronic weight management. As a condition of approval, the FDA required a long-term trial to show that the drug did not raise cardiovascular risk. CAMELLIA-TIMI 61 randomized 12,000 overweight or obese patients at high cardiovascular risk to lorcaserin or placebo. Its primary result was reassuring: major cardiovascular events occurred at 2.0% per year with lorcaserin and 2.1% with placebo, and more patients lost at least 5% of body weight (Bohula et al., 2018).
The FDA's review of the trial's complete data told a different story about cancer. More patients taking lorcaserin were diagnosed with cancer than those taking placebo, 7.7% against 7.1%, roughly one additional cancer for every 470 patients treated for a year, spread across several types including pancreatic, colorectal and lung cancer (Sharretts et al., 2020). The trial was not designed to study cancer, and no single mechanism explained the finding. But the FDA judged that the modest weight loss benefit did not outweigh a possible cancer risk, and in February 2020 it requested that the manufacturer withdraw the drug, which it did voluntarily.
ELSI Appraisal
Ethical
The lorcaserin case shows the duty to act on uncertain evidence. A small imbalance, not designed into the trial's questions, was still enough to tip the balance for a drug whose benefit was modest.
Legal
The FDA's authority to require the outcomes trial as a condition of approval made the finding possible. Without that requirement, the signal might never have emerged.
Social
Patients who had used the drug for years were told to stop and talk with their clinicians, but no cancer screening beyond usual care was recommended, which may have left some uncertain about their own risk.
Proposed Improvements
Require longer follow-up of safety outcomes in outcome trials for chronic-use drugs, publish disproportionality analyses from the adverse event database more often and give patients plain-language summaries when a drug is withdrawn.
Conclusion
Postmarket monitoring combines mandatory manufacturer reporting, voluntary reports, active surveillance and large trials. The lorcaserin withdrawal shows the system working as intended: a requirement imposed at approval produced the data that removed the drug when its risks came to outweigh its benefits.
References
Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., Garcia-Castillo, A., Gupta, M., Leiter, L. A., Weissman, N. J., White, H. D., Patel, T., Francis, B., Miao, W., Perdomo, C., . . . Scirica, B. M. (2018). Cardiovascular safety of lorcaserin in overweight or obese patients. New England Journal of Medicine, 379(12), 1107-1117. https://doi.org/10.1056/NEJMoa1808721
Definitions, 21 C.F.R. § 7.3 (2025).
Postmarketing reporting of adverse drug experiences, 21 C.F.R. § 314.80 (2025).
Sharretts, J., Galescu, O., Gomatam, S., Andraca-Carrera, E., Hampp, C., & Yanoff, L. (2020). Cancer risk associated with lorcaserin: The FDA's review of the CAMELLIA-TIMI 61 trial. New England Journal of Medicine, 383(11), 1000-1002. https://doi.org/10.1056/NEJMp2003873
What the HCR 555 Module 3 instructions ask for
Week 3 of HCR 555 covers data monitoring, reporting requirements, safety signals and the tools regulators use when a problem appears: boxed warnings, Dear Doctor letters, MedWatch and voluntary and mandatory recalls with their classification. Assignment 3 asks for a report that brings those pieces together. The syllabus lists five elements: the data monitoring and reporting requirements for pharmaceuticals, safety signals, the evaluation of safety data, the processes for recalls, warnings and adverse effect reporting and an example of a drug withdrawn because of a safety signal. Because the assignment is called a report, headings that match those elements help the grader find each one. It is worth 100 points and, like every HCR 555 paper, is scored on critical appraisal, the ELSI framework and mechanics. Choose a withdrawal example with published regulatory reasoning, so you can explain why the agency acted.
Inside the HCR 555 Module 3 example
The report opens by explaining why safety knowledge is incomplete at approval. Sections then follow the syllabus's elements in order: reporting requirements before and after approval, with the regulation for postmarketing reports; what a signal is and how it is evaluated, including why spontaneous reports cannot give a rate; and a table of regulatory tools from labeling changes to withdrawal, followed by the three recall classes cited to the regulation. The lorcaserin example traces the drug from approval through the required outcomes trial to the FDA's review and withdrawal, using the trial publication and the FDA reviewers' own account. A short ELSI appraisal, three proposed improvements and a conclusion that ties the example back to the system finish the report.
Where the marks sit in the HCR 555 Module 3 rubric
The monitoring report earns its content marks by explaining premarket and postmarket reporting requirements accurately, defining a safety signal and showing how one is evaluated, describing warnings, recalls and their classes correctly and using a withdrawn drug as a well-documented example that shows the system at work. ELSI analysis and proposed solutions count in content too. Points are lost when recall classes are confused, when a recall is treated as the same thing as a withdrawal, when the withdrawn drug is described from news coverage without regulatory sources and when the report never evaluates safety data, only describes it. Mechanics are graded as in the other HCR 555 papers. A well-chosen example, with numbers from the trial or review that triggered the action, usually distinguishes the strongest reports.
HCR 555 Module 3 help from the desk
Organize the report under the five elements the syllabus lists. Look up 21 C.F.R. § 314.80 for postmarketing reporting and § 7.3 for recall classes rather than relying on summaries. Explain the difference between a recall of defective lots and a withdrawal of the drug itself. For your example, find the FDA's own reasoning, in a Drug Safety Communication or a published FDA review, and report the numbers. Avoid the most worn examples if your instructor asks for originality. Add an ELSI section with a solution for each issue. If you want help choosing a withdrawal with good public documentation, the desk can suggest options.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCR 555 and MS in Regulatory Science sample papers
- HCR 555 Module 1: Assignment 1: Drug Development From Bench to Market
- HCR 555 Module 2: Assignment 2: Risk-Benefit Analysis of Two Drugs
- HCR 555 Module 5: Assignment 4: Globalization, Off-Label Use, Biologics and Counterfeits
- HCR 555 Module 6: Assignment 5: A Pharmacogenomic Risk-Minimization Plan
- HCR 579 Module 6: Assignment 4: Presenting a Precision Medicine Protocol
- HCR 576 Module 7: Paper: Comparing the U.S. and EU Regulatory Frameworks
- HCR 563 Module 5: Assignment 3: Annotated Bibliography on Decentralized Trials
- HCR 543 Module 7: Summative Evaluation Paper: Emerging Food Safety Issues
HCR 555 Module 3 questions, answered
Where can I find a free HCR 555 Module 3 sample paper?
Above on this page is a complete Assignment 3 report on drug safety monitoring, recalls and the 2020 withdrawal of lorcaserin.
What are the three FDA recall classes?
Class I for products likely to cause serious harm or death, Class II for temporary or remote harm and Class III for products unlikely to cause harm.
How fast must manufacturers report serious adverse drug events?
Serious and unexpected postmarketing events go to the FDA within 15 calendar days under 21 C.F.R. § 314.80.
What is a drug safety signal?
Information suggesting a new possible risk, or a new aspect of a known risk, that needs further evaluation.
Why was lorcaserin withdrawn?
A cardiovascular outcomes trial found more cancer diagnoses with lorcaserin than placebo, 7.7% against 7.1%, and FDA judged the risk outweighed its benefit.